Biologics Market Poised for Substantial Growth: Projected to Reach USD 690 Billion by 2030
According to Next Move Strategy Consulting, the global Biologics Market, is expected to experience significant growth, reaching USD 690 billion by 2030, growing at a compound annual growth rate (CAGR) of 9% by 2030.
Biologics, or biological drugs, are medications derived from living organisms, offering innovative treatments for a wide range of diseases including cancer, autoimmune disorders, and chronic diseases such as diabetes and cardiovascular diseases.
Download Free Sample: https://www.nextmsc.com/biologics-market/request-sample
Biologics have revolutionized the treatment landscape, particularly in chronic disease management, through their ability to modify immune responses and regulate vital proteins and hormones. These drugs are predominantly administered via injection or infusion due to their protein-based composition, which can be easily broken down if taken orally. The growing prevalence of chronic conditions like rheumatoid arthritis, cancer, and cardiovascular diseases has led to a surge in the demand for biologics. Notably, cancer treatment, where biologics like monoclonal antibodies and antibody-drug conjugates are increasingly utilized, is a major growth driver in the sector.
Market Dynamics and Growth Drivers
Several key factors are fueling the expansion of the biologics market. One of the foremost drivers is the increasing prevalence of chronic diseases. According to the World Health Organization (WHO), cardiovascular diseases alone accounted for nearly 18 million deaths in 2019, highlighting the rising need for effective treatment options. Furthermore, the success and high demand for innovative therapies such as immunotherapies and targeted therapies have significantly contributed to the growth of biologics. For instance, the WHO reported that cancer was responsible for approximately 10 million deaths worldwide in 2020, further underscoring the importance of biologics in oncology treatment.
The introduction of novel biologics such as antibody-drug conjugates (ADCs) is also accelerating market growth due to their high efficacy in treating cancer. Despite these growth opportunities, challenges such as high initial capital investment and the risk of side effects, including gastrointestinal issues and breathing difficulties, remain significant hurdles. However, the rising shift towards personalized medicine, along with the increasing use of biopharmaceuticals over traditional chemically-synthesized drugs, promises a robust outlook for the biologics market.
Inquire Before Buying: https://www.nextmsc.com/biologics-market/inquire-before-buying
Market Segmentation and Insights
The biologics market is segmented into several categories, including type, manufacturing capabilities, drug classification, and geographical region. Key therapeutic areas include cancer, immunological disorders, infectious diseases, and hematologic disorders, among others. The market is also categorized based on the source of biologics, such as microbial and mammalian sources, and the mode of administration, with injectable biologics being the predominant route.
Geographical Insights
North America remains the dominant region in the biologics market, owing to its advanced research infrastructure, significant pharmaceutical investments, and the high prevalence of diseases treatable by biologics. The recent approval of CARVYKTI by the U.S. FDA in 2022, a treatment for relapsed multiple myeloma, exemplifies the region's ongoing role as a leader in biologic drug development.
Meanwhile, the Asia-Pacific region is rapidly emerging as a key growth area due to increasing regulatory approvals for biologics and a growing patient pool for chronic diseases such as diabetes and cancer. The launch of biologics like NuPTH and Cadalimab by Cadila Pharmaceuticals in India in 2021 reflects the region's expanding role in the biologics sector.
Competitive Landscape
Prominent market players, including Biocon Biologics Ltd., Bristol-Myers Squibb, Merck & Co., Eli Lilly, AstraZeneca, Novartis, Pfizer, Amgen, and Moderna, are actively engaged in biologics research, development, and commercialization. The introduction of new biosimilars and biologic treatments, such as Biocon's Semglee for diabetes and GSK's Nucala for Hypereosinophilic Syndrome, underscores the competitive nature of this sector.
Conclusion
The biologics market is experiencing a dynamic period of growth, driven by increasing demand for advanced treatments, particularly in the oncology and autoimmune disease segments. Innovations in drug development and the expansion of biologic treatments to address chronic diseases are positioning the market for sustained growth in the coming decade. While challenges remain, including high costs and side effect risks, the industry's shift toward personalized medicine and biopharmaceuticals presents ample opportunities for growth and development.
Also, Browse Related Reports:
For more information, please contact:
Next Move Strategy Consulting
E-Mail: info@nextmsc.com
Direct: +1-217-650-7991
Website: www.nextmsc.com
Follow Us: LinkedIn | Twitter | Facebook | Instagram | YouTube
About Next Move Strategy Consulting:
Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to provide strategically analysed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes Next Move different from the rest is its top-quality research and the obsession of turning data into knowledge by dissecting every bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations with industry experts across a diverse range of industry sectors. The high-quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to take critical business decisions that enables them to move beyond time and have competitive edge in the industry.
We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicates as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that range from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.